{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:23:09Z","timestamp":1788484989083,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Rio Hortega Programme"},{"name":"National Institute of Health Carlos III"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,23]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n In dialysis patients, non-adherence to oral cinacalcet adds complexity to the control of secondary hyperparathyroidism. The present study aims to evaluate the use of intravenous calcimimetic, etelcalcetide, in the control of secondary hyperparathyroidism in patients adherent and non-adherent to oral calcimimetics.<\/jats:p>\n <\/jats:sec>\n \n Method<\/jats:title>\n The Simplified Medication Adherence Questionnaire was used to identify non-adherence. Almost half of the patients were non-adherent to the treatment with cinacalcet. Twenty-five patients (15 non-adherent) were switched from cinacalcet to etelcalcetide and were followed-up monthly for 8 months.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Cinacalcet was discontinued for 1 week before the initiation of etelcalcetide. After this period, the serum PTH levels increased by2-fold in adherent patients, whereas it did not change in non-adherent patients suggesting that they were not taking the medication. Etelcalcetide progressively reduced serum parathyroid hormone (PTH) (mean \u00b1 standard deviation) from 818\u2009\u00b1\u2009395 to 367\u2009\u00b1\u2009289 pg\/mL (P\u2009&lt;\u20090.001) in non-adherents, and from 496\u2009\u00b1\u2009172 to 228\u2009\u00b1\u2009111 pg\/mL (P\u2009&lt;\u20090.01) in adherent patients with a mean dose of 7.0\u2009\u00b1\u20092.3 and 5.1\u2009\u00b1\u20091.2 mg in non-adherent and in adherent patients, respectively. Etelcalcetide increased the percentage of patients with PTH on target from 28% to 58%. Patients with serum calcium &lt;8.4 mg\/dL increased from 8% to 40%, although they remained asymptomatic. The percent of patients with serum phosphate on target increased from 40% to 65%.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The lack of adherence to cinacalcet is a possible cause of the apparent lack of response to oral calcimimetic. The use of etelcalcetide ensures compliance and control of secondary hyperparathyroidism in both non-adherent and adherent patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/ckj\/sfaa005","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T12:11:01Z","timestamp":1579090261000},"page":"840-846","source":"Crossref","is-referenced-by-count":15,"title":["Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics"],"prefix":"10.1093","volume":"14","author":[{"given":"Maria Dolores","family":"Arenas","sequence":"first","affiliation":[{"name":"Nephrology Department, Vithas Perpetuo Socorro International, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Rodelo-Haad","sequence":"additional","affiliation":[{"name":"Maimonides Biomedical Research Institute of Cordoba (IMIBIC)\/Reina Sofia University Hospital\/University of Cordoba, Cordoba, Spain"},{"name":"Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain"},{"name":"RETICs-REDinREN (National Institute of Health Carlos III), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Victoria Pend\u00f3n-Ruiz","family":"de Mier","sequence":"additional","affiliation":[{"name":"Maimonides Biomedical Research Institute of Cordoba (IMIBIC)\/Reina Sofia University Hospital\/University of Cordoba, Cordoba, Spain"},{"name":"Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain"},{"name":"RETICs-REDinREN (National Institute of Health Carlos III), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Maimonides Biomedical Research Institute of Cordoba (IMIBIC)\/Reina Sofia University Hospital\/University of Cordoba, Cordoba, Spain"},{"name":"Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain"},{"name":"RETICs-REDinREN (National Institute of Health Carlos III), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"2021032313072351000_sfaa005-B1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1474-5151(03)00091-4","article-title":"Adherence to long-term therapies: evidence for action","volume":"2","author":"De Geest","year":"2003","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2021032313072351000_sfaa005-B2","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"2021032313072351000_sfaa005-B3","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2021032313072351000_sfaa005-B4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11255-005-0083-x","article-title":"K\/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?","volume":"38","author":"Wei","year":"2006","journal-title":"Int Urol Nephrol"},{"key":"2021032313072351000_sfaa005-B5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bone.2017.08.026","article-title":"Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism","volume":"105","author":"Li","year":"2017","journal-title":"Bone"},{"key":"2021032313072351000_sfaa005-B6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1744-9987.2010.00843.x","article-title":"Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients","volume":"14","author":"Hirai","year":"2010","journal-title":"Ther Apher Dial"},{"key":"2021032313072351000_sfaa005-B7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"2021032313072351000_sfaa005-B8","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3111\/13696998.2011.627404","article-title":"Association of cinacalcet adherence and costs in patients on dialysis","volume":"14","author":"Lee","year":"2011","journal-title":"J Med Econ"},{"key":"2021032313072351000_sfaa005-B9","doi-asserted-by":"crossref","first-page":"104892","DOI":"10.1155\/2013\/104892","article-title":"Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: results of a prospective randomized controlled study","volume":"2013","author":"Forni Ogna","year":"2013","journal-title":"BioMed Res Int"},{"key":"2021032313072351000_sfaa005-B10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1542-4758.2009.00397.x","article-title":"Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients","volume":"14","author":"Gincherman","year":"2010","journal-title":"Hemodial Int"},{"key":"2021032313072351000_sfaa005-B11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"2021032313072351000_sfaa005-B12","doi-asserted-by":"crossref","first-page":"e0144119","DOI":"10.1371\/journal.pone.0144119","article-title":"Nonadherence to medication therapy in haemodialysis patients: a systematic review","volume":"10","author":"Ghimire","year":"2015","journal-title":"PloS One"},{"key":"2021032313072351000_sfaa005-B13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","article-title":"Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study","volume":"16","author":"Knobel","year":"2002","journal-title":"AIDS"},{"key":"2021032313072351000_sfaa005-B14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ndt\/gfu015","article-title":"Drug adherence in chronic kidney diseases and dialysis","volume":"30","author":"Burnier","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2021032313072351000_sfaa005-B15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/08870440290001502","article-title":"Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication","volume":"17","author":"Horne","year":"2002","journal-title":"Psychol Health"},{"key":"2021032313072351000_sfaa005-B16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2215\/CJN.07050714","article-title":"A randomized trial of cinacalcet versus vitamin D Analogs as monotherapy in secondary hyperparathyroidism (PARADIGM)","volume":"10","author":"Wetmore","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021032313072351000_sfaa005-B17","author":"Bushinsky","year":"2019"},{"key":"2021032313072351000_sfaa005-B18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bcp.12194","article-title":"What are validated self-report adherence scales really measuring?: a systematic review","volume":"77","author":"Nguyen","year":"2014","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/3\/840\/36670563\/sfaa005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/3\/840\/36670563\/sfaa005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T13:11:58Z","timestamp":1616505118000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/14\/3\/840\/5734680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2,12]]},"published-print":{"date-parts":[[2021,3,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaa005","relation":{},"ISSN":["2048-8513"],"issn-type":[{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,2,12]]}}}